TABLE 3.
Percentage of patients response to adalimumab at week 12.
| Variable | Total number | Respond n, frequency (%) | ||
|---|---|---|---|---|
| Disease location, n(%) a | Pearson χ2 | p value | ||
| L1 (ileal disease) | 22 | 10 (45.5) | 0.409 | 0.815 |
| L2 (colonic disease) | 18 | 10 (55.6) | ||
| L3 (ileocolonic disease) | 75 | 37 (49.3) | ||
| L4 (upper gastrointestinal disease) | 2 | 0 | ||
| Previous failed treatment | Fisher’s exact test | p value | ||
| No treatment | 66 | 36 (54.5) | 8.133 | 0.041 b |
| Infliximab | 26 | 8 (30.8) | ||
| Steroids | 12 | 4 (33.3) | ||
| Infliximab & Steroids | 11 | 2 (18.2) | ||
| CD surgical history | ||||
| Any surgery before baseline | 26 | 15 (57.7) | ||
| Surgery within 12 w of baseline | 8 | NA |
a
Patients could have multiple CD locations. Patients with both colonic and ileal CD were categorized as ileal-colonic. The locations of colonic, ileal, and ileal-colonic did not overlap. The locations of ileal-colonic ovedaped with upper gastrointestinal disease.
b
No statistical significance of paired comparison due to p > a (0.0125) after Bonferroni adjustment.